News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Akums Drugs will undertake this development and commercialization in India
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Subscribe To Our Newsletter & Stay Updated
